trial · primary record
PAS-004 Tablets
NF1 Mutation
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 56 |
| Primary completion | 2028-02 |
| Primary endpoint | Part A: To evaluate the safety and tolerability of PAS-004 when administered for one 28-day treatment cycle |
| Registry ID | NCT06961565 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:41:38.124Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06961565
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.